Huntington National Bank Sells 9,727 Shares of Thermo Fisher Scientific Inc. $TMO

Huntington National Bank trimmed its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 12.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 70,671 shares of the medical research company’s stock after selling 9,727 shares during the quarter. Huntington National Bank’s holdings in Thermo Fisher Scientific were worth $40,950,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the business. Unified Investment Management boosted its position in shares of Thermo Fisher Scientific by 2.2% in the fourth quarter. Unified Investment Management now owns 1,069 shares of the medical research company’s stock valued at $619,000 after acquiring an additional 23 shares during the period. Texas Capital Bank Wealth Management Services Inc boosted its position in shares of Thermo Fisher Scientific by 54.7% in the fourth quarter. Texas Capital Bank Wealth Management Services Inc now owns 1,502 shares of the medical research company’s stock valued at $870,000 after acquiring an additional 531 shares during the period. Waystone Advisors LLC acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at $217,000. Geode Capital Management LLC raised its stake in shares of Thermo Fisher Scientific by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 8,196,477 shares of the medical research company’s stock valued at $4,728,129,000 after purchasing an additional 26,425 shares in the last quarter. Finally, Fidelis Capital Partners LLC raised its stake in shares of Thermo Fisher Scientific by 10.3% in the fourth quarter. Fidelis Capital Partners LLC now owns 6,092 shares of the medical research company’s stock valued at $3,530,000 after purchasing an additional 570 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the transaction, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of the firm’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at approximately $63,499,170. This trade represents a 3.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Stifel Nicolaus cut their target price on Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a research note on Friday, April 24th. Morgan Stanley restated an “overweight” rating and issued a $620.00 target price on shares of Thermo Fisher Scientific in a research note on Monday, April 27th. DZ Bank assumed coverage on Thermo Fisher Scientific in a research note on Friday, March 27th. They issued a “buy” rating and a $610.00 target price for the company. UBS Group restated a “neutral” rating and issued a $615.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. Finally, Barclays cut their target price on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a research note on Tuesday, April 14th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $616.10.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock opened at $456.64 on Thursday. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. The stock has a fifty day moving average price of $479.12 and a two-hundred day moving average price of $535.54. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $643.99. The firm has a market capitalization of $169.70 billion, a P/E ratio of 25.10, a P/E/G ratio of 1.98 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. During the same period in the prior year, the company posted $5.15 earnings per share. The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.34%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.